XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Stock compensation and other employee benefit plans (Tables)
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock compensation expense

Stock compensation expense for each period was as follows:

(in thousands)

 

2021

 

 

2020

 

 

2019

 

Cost of revenue

 

$

8,094

 

 

$

322

 

 

$

176

 

Research and development

 

 

3,657

 

 

 

57

 

 

 

51

 

Selling and marketing

 

 

2,056

 

 

 

38

 

 

 

26

 

General and administrative

 

 

47,958

 

 

 

1,401

 

 

 

653

 

Total stock compensation expense

 

$

61,765

 

 

$

1,818

 

 

$

906

 

Summary of outstanding option awards activity

Information relating to our outstanding option awards was as follows:

Options

 

Shares

 

 

Weighted-average exercise price

 

 

Weighted-average remaining contractual term (in years)

 

 

Average intrinsic value (in thousands)

 

Outstanding as of December 31, 2020

 

 

8,524,997

 

 

$

0.23

 

 

 

 

 

 

 

Granted

 

 

2,107,500

 

 

 

8.14

 

 

 

 

 

 

 

Exercised

 

 

(2,838,464

)

 

 

0.11

 

 

 

 

 

 

 

Forfeited and expired

 

 

(255,768

)

 

 

0.48

 

 

 

 

 

 

 

Outstanding as of December 31, 2021

 

 

7,538,265

 

 

$

2.48

 

 

 

7.41

 

 

$

39,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested at December 31, 2021 or expected to vest in the future

 

 

7,538,265

 

 

$

2.48

 

 

 

7.41

 

 

$

39,500

 

Exercisable at December 31, 2021

 

 

4,253,458

 

 

$

0.24

 

 

 

6.23

 

 

$

31,139

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At December 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation cost not yet recognized (in thousands)

 

 

 

 

 

 

 

 

 

 

$

10,301

 

Weighted-average remaining expense recognition period (in years)

 

 

 

 

 

 

 

 

 

 

 

5.03

 

 

Summary of option awards Activity

Assumptions used to value option awards were as follows:

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Black-Scholes-Merton pricing formula weighted-average assumptions:

 

 

 

 

 

 

 

 

 

Expected life (in years)

 

 

7.72

 

 

 

6.07

 

 

 

5.92

 

Risk-free interest rate

 

1.32%

 

 

1.60%

 

 

1.94%

 

Volatility

 

56.47%

 

 

51.57%

 

 

52.90%

 

Dividend yield

 

0.00%

 

 

0.00%

 

 

0.00%

 

 

 

 

 

 

 

 

 

 

 

Valuations:

 

 

 

 

 

 

 

 

 

Grant-date fair value per option (post-split)

 

$

4.79

 

 

$

2.86

 

 

$

1.29

 

Intrinsic value of options exercised (in thousands)

 

$

22,852

 

 

$

 

 

$

 

Average intrinsic value per share of options exercised

 

$

8.05

 

 

$

 

 

$

 

Summary of outstanding restricted stock unit and restricted stock awards

Information relating to our outstanding restricted stock unit and restricted stock awards was as follows:

 

 

Shares

 

 

Weighted-average grant date fair value

 

Restricted stock units:

 

 

 

 

 

 

Nonvested as of December 31, 2020

 

 

12,943,811

 

 

$

3.15

 

Granted

 

 

5,470,137

 

 

 

7.72

 

Vested

 

 

(12,883,918

)

 

 

3.87

 

Forfeited

 

 

(388,561

)

 

 

4.68

 

Nonvested as of December 31, 2021

 

 

5,141,469

 

 

$

6.08

 

 

 

 

 

 

 

 

Restricted stock awards:

 

 

 

 

 

 

Nonvested as of December 31, 2020

 

 

1,169,601

 

 

$

0.07

 

Granted

 

 

 

 

 

 

Vested

 

 

(1,169,601

)

 

 

0.07

 

Forfeited

 

 

 

 

 

 

Nonvested as of December 31, 2021

 

 

 

 

$

 

 

 

 

 

 

 

 

At December 31, 2021:

 

 

 

 

 

 

Stock-based compensation cost not yet recognized (in thousands)

 

 

 

 

$

21,396

 

Weighted-average remaining expense recognition period (in years)

 

 

 

 

 

2.95